About us

About us


Oncomedics is a biotechnology company specializing in individualized therapy for the treatment of cancer. The company was founded in 2006 by Dr Christophe Lautrette and Stéphanie Giraud. Oncomedics moved in 2010 to new laboratories specifically adapted for the needs of its business. These premises are located on the site of ESTER Technopolis, Limoges (France). Oncomedics is now composed of 4 people including 3 PhDs and has numerous collaborations with clinical centers and academic laboratories. During the company creation, Oncomedics has established a network of clinicians needed to supply tumor samples with the addition of new tumor types. Surgeons advise patients, evidence of their consent for the use of their surgical residues and perform biopsies or complete resection of the affected organ. Pathologists, after making their diagnosis, extract a dedicated Oncomedics tumor fragment and send it to Oncomedics by specialized carrier. These procedures are performed with a legal contract with Oncomedics.


  • In 2006, Oncomedics receives € 240,000 grant from OSEO/Région Limousin for further research and therapeutic development of its Oncogramme program that may lead to the ready to use assay to define the sensitivity of a patient cancer to clinically available chemotherapy drugs.
  • In 2010, Oncomedics receives € 100,000 grant from Région Limousin/FEDER for further research of its tumor biocapteur program that may lead to a rupture technology for tumor cell detection and characterization.
  • In 2013, as partner of the IMODI project, Oncomedics receives € 630,000 grant from BPI France for further research to develop new experimental primary cell culture conditions to increase the number of cancer indications for its OncoTRIP platform.
  • In 2014, Oncomedics receives € 100,000 grant from Région Limousin/FEDER for further research of its tumor biocapteur program applied to colorectal cancer (CCREMS Biocpateur). This program may lead to a non labelled and automated rupture technology for colorectal tumor cell detection and characterization.


Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer.

Bounaix Morand du Puch C, Nouaille M, Giraud S, Labrunie A, Luce S, Preux PM, Labrousse F, Gainant A, Tubiana-Mathieu N, Le Brun-Ly V, Valleix D, Guillaudeau A, Mesturoux L, Coulibaly B, Lautrette C, Mathonnet M.

J Transl Med. 2016 Jan 12;14(1):10.


Sedimentation field flow fractionation monitoring of in vitro enrichment in cancer stem cells by specific serum-free culture medium.

Mélin C, Perraud A, Bounaix Morand du Puch C, Loum E, Giraud S, Cardot P, Jauberteau MO, Lautrette C, Battu S, Mathonnet M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 15;963:40-6.


Discrimination of colorectal cancer cell lines using microwave biosensors.

Zhang LY, Bounaix Morand du Puch C, Dalmay C, Lacroix A, Landoulsi A, Leroy J, Mélin C, Lalloué F, Battu S, Lautrette C, Giraud S, Bessaudou A, Blondy P, Jauberteau MO, Pothier A.

Sensors and Actuators A 216 (2014) 405–416.


Oncogramme, an Adapted Method for Individualized Tumour Response Testing of Ovary Cancer Treatments.

Giraud S, Croce S, Bessette B, Stoeckle E, Guyon F, Mac Grogan G, Floquet A,  Velasco V, Mannina C, Lautrette C.

J Cancer Res Therap Oncol. 2014; 2: 1-9.


Improved sedimentation field-flow fractionation separation channel for concentrated cellular elution.

Mélin C, Lacroix A, Lalloué F, Pothier A, Zhang LY, Perraud A, Dalmay C, Lautrette C, Jauberteau MO, Cardot P, Mathonnet M, Battu S.

J Chromatogr A. 2013 Aug 9;1302:118-24.


Decrease in Fas-induced apoptosis by the γ-secretase inhibitor is dependent on p75(NTR) in a glioblastoma cell line.

Bessette B, Durand K, Giraud S, Bégaud G, Mathonnet M, Lalloué F.

Exp Ther Med. 2012 May;3(5):873-877.


Oncogramme responses of breast tumour cells treated with herceptin correlate with HER2/C-ERB B2 pathological status.

Giraud S, Bounaix Morand du Puch C, Fermeaux V, Guillaudeau A, Lautrette C.

Anticancer Res. 2012 Apr;32(4):1323-5.


P75 neurotrophin receptor is sequestered in the Golgi apparatus of the U-87 MG human glioblastoma cell line.

Giraud S, Loum E, Bessette B, Mathonnet M, Lalloué F.

Int J Oncol. 2011 Feb;38(2):391-9.


Oncogramme, a new promising method for individualized breast tumour response testing for cancer treatment.

Giraud S, Loum E, Bessette B, Fermeaux V, Lautrette C.

Anticancer Res. 2011 Jan;31(1):139-45.


Oncogramme, a new individualized tumor response testing method: application to colon cancer.

Loum E, Giraud S, Bessette B, Battu S, Mathonnet M, Lautrette C.

Cytotechnology. 2010 Oct;62(5):381-8.


In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats.

Giraud S, Bessette B, Boda C, Lalloué F, Petit D, Mathonnet M, Jauberteau MO.

Int J Oncol. 2007 Jan;30(1):273-81


Increase of Fas-induced apoptosis by inhibition of extracellular phosphorylation of Fas receptor in Jurkat cell line.

Lautrette C, Loum-Ribot E, Petit D, Vermot-Desroches C, Wijdenes J, Jauberteau MO.

Apoptosis. 2006 Jul;11(7):1195-204.


Modulation of Fas-induced apoptosis by p75 neurotrophin receptor in a human neuroblastoma cell line.

Giraud S, Lautrette C, Bessette B, Decourt C, Mathonnet M, Jauberteau MO.

Apoptosis. 2005 Dec;10(6):1271-83.


Endothelial cell activation in the presence of African trypanosomes.

Girard M, Giraud S, Courtioux B, Jauberteau-Marchan MO, Bouteille B.

Mol Biochem Parasitol. 2005 Jan;139(1):41-9


Sedimentation field flow fractionation purification of immature neural cells from a human tumor neuroblastoma cell line.

Lautrette C, Cardot PJ, Vermot-Desroches C, Wijdenes J, Jauberteau MO, Battu S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):149-60.


Expression of a functional Fas death receptor by human foetal motoneurons.

Lautrette C, Giraud S, Vermot-Desroches C, Preud’homme JL, Jauberteau MO.

Neuroscience. 2003;119(2):377-85.


In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients.

Yi FH, Lautrette C, Vermot-Desroches C, Bordessoule D, Couratier P, Wijdenes J, Preud’homme JL, Jauberteau MO.

J Neuroimmunol. 2000 Sep 22;109(2):211-20.